R34M (p.Arg34Met) variant of ABL2 (Tyrosine-protein kinase ABL2)
R34M (p.Arg34Met) in ABL2 (Tyrosine-protein kinase ABL2) is a missense change. Clinical records from UniProt describe it as variant assessed as somatic; moderate impact. The available variant effect predictions contribute to a CATVariant prioritization score of 0.36 / 1. The record also includes population frequency data.
R34M (p.Arg34Met) variant details
- p.Arg34Met
- NCI-TCGA TCGA novel
- Variant assessed as somatic; moderate impact.
- Missense
- Variant Prioritization Score for Impact Estimate 0.363
- REVEL 0.30
- CADD 23.40
- PolyPhen-2 0.07
- SIFT 0.02
- UniProt: Variant assessed as somatic; moderate impact.
- Population evidence available